New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:12 EDTBAYRY, CGENCompugen achieves initial milestone in collaboration with Bayer HealthCare
Compugen Ltd. (CGEN) disclosed hat it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2M payment out of the $30M potential milestone payments associated with joint preclinical research for the two programs. The collaboration and license agreement provides the framework for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen are jointly pursuing a preclinical research program for each of the two candidates. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the terms of the agreement, Compugen has received an upfront payment of $10M and is eligible to receive over $500M in potential milestone payments for both checkpoint programs, plus an additional $30M of potential milestone payments associated with joint preclinical research for the two programs. Compugen is also eligible to receive royalties on global net sales from any resulting products under the collaboration.
News For CGEN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
12:17 EDTBAYRYBayer, Cardinal Health sign contract manufacturing agreement for Xofigo
Subscribe for More Information
07:07 EDTCGENCompugen enters into research collaboration with Johns Hopkins University
Compugen announced the initiation of a multi-year research collaboration with Johns Hopkins University, School of Medicine, under the direction of Prof. Drew Pardoll and Dr. Charles Drake. Prof. Pardoll and Dr. Drake, members of Compugenís Scientific Advisory Board, are pioneers in the field of immuno-oncology. The collaboration will focus on further evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. This evaluation will include the candidatesí differentiation profile with respect to known checkpoints and their potential to serve either for monotherapy or in combination with other cancer treatments. This collaborative research will expand Compugenís ongoing assessment of the biology and mechanism of actions of its novel B7/CD28-like immune checkpoint proteins, and provide access to the world-class immuno-oncology research tools and expertise at Johns Hopkins University. The specific studies under the collaboration will assist Compugen in further substantiating the potential of its novel proteins as targets for cancer immunotherapy. It is anticipated that the results of this collaboration will significantly broaden the underlying scientific knowledge of Compugenís targets and will support their translation toward the clinic.
December 16, 2014
08:11 EDTBAYRYFoamix earns $2.5M milestone payment from Bayer
Subscribe for More Information
December 10, 2014
07:56 EDTBAYRYUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
December 9, 2014
12:22 EDTBAYRYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:38 EDTBAYRYBayer downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use